Volume 22 Number 4 Fall 2022
Myeloma Today A publication of the International Myeloma Foundation
TECVAYLI™ (teclistamab-cqyv) Receives Accelerated Approval The first-in-class bispecific BCMA-directed CD3 T-cell engager is FDA-approved for the treatment of adult patients with relapsed or refractory myeloma PAGE 5
TECVAYLITM
T cell Myeloma cell
Tecvayli activates the T cell to release cytotoxic granules that kill the myeloma cell
Also in this edition: } Myeloma Treatment Options
for Patients in Early Relapse: Dr. Joseph Mikhael discusses the surge in options for patients with myeloma after 1–3 prior lines of therapy. PAGE 6
} CAR T-cell Therapies
for Patients in Late Relapse: Dr. Adam Cohen discusses treatment with ABECMA® or CARVYKTI® for patients with myeloma after 4 or more prior lines of therapy. PAGE 7
This edition of Myeloma Today is supported by Amgen • Bristol Myers Squibb • Janssen Oncology • Karyopharm Therapeutics • Legend Biotech • Sanofi • Takeda Oncology